Semantic inference using chemogenomics data for drug discovery

被引:10
|
作者
Zhu, Qian [1 ]
Sun, Yuyin [2 ]
Challa, Sashikiran [1 ]
Ding, Ying [2 ]
Lajiness, Michael S. [3 ]
Wild, David J. [1 ]
机构
[1] Indiana Univ, Sch Informat & Comp, Bloomington, IN 47408 USA
[2] Indiana Univ, Sch Lib & Informat Sci, Bloomington, IN 47408 USA
[3] Eli Lilly & Co, Indianapolis, IN 46225 USA
来源
BMC BIOINFORMATICS | 2011年 / 12卷
关键词
Clozapine; Resource Description Framework; Ergot Alkaloid; Methysergide; SPARQL Query;
D O I
10.1186/1471-2105-12-256
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Semantic Web Technology (SWT) makes it possible to integrate and search the large volume of life science datasets in the public domain, as demonstrated by well-known linked data projects such as LODD, Bio2RDF, and Chem2Bio2RDF. Integration of these sets creates large networks of information. We have previously described a tool called WENDI for aggregating information pertaining to new chemical compounds, effectively creating evidence paths relating the compounds to genes, diseases and so on. In this paper we examine the utility of automatically inferring new compound-disease associations (and thus new links in the network) based on semantically marked-up versions of these evidence paths, rule-sets and inference engines. Results: Through the implementation of a semantic inference algorithm, rule set, Semantic Web methods (RDF, OWL and SPARQL) and new interfaces, we have created a new tool called Chemogenomic Explorer that uses networks of ontologically annotated RDF statements along with deductive reasoning tools to infer new associations between the query structure and genes and diseases from WENDI results. The tool then permits interactive clustering and filtering of these evidence paths. Conclusions: We present a new aggregate approach to inferring links between chemical compounds and diseases using semantic inference. This approach allows multiple evidence paths between compounds and diseases to be identified using a rule-set and semantically annotated data, and for these evidence paths to be clustered to show overall evidence linking the compound to a disease. We believe this is a powerful approach, because it allows compound-disease relationships to be ranked by the amount of evidence supporting them.
引用
收藏
页数:12
相关论文
共 50 条
  • [22] Kinase chemogenomics: Targeting the human kinome for target validation and drug discovery
    ter Haar, E
    Walters, WP
    Pazhanisamy, S
    Taslimi, P
    Pierce, AC
    Bemis, GW
    Salituro, FG
    Harbeson, SL
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (03) : 235 - 253
  • [23] Chemogenomics in drug discovery: computational methods based on the comparison of binding sites
    Vulpetti, Anna
    Kalliokoski, Tuomo
    Milletti, Francesca
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (15) : 1971 - 1979
  • [24] Collaborative Drug Discovery : Inference-level Data Protection Perspective
    Pejo, Balazs
    Remeli, Mina
    Arany, Adam
    Galtier, Mathieu
    Acs, Gergely
    TRANSACTIONS ON DATA PRIVACY, 2022, 15 (02) : 87 - 107
  • [25] Targeting trypanosomes: how chemogenomics and artificial intelligence can guide drug discovery
    Landaburu, Lionel Uran
    Garnham, Mercedes Didier
    Aguero, Fernan
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2023, 51 (01) : 195 - 206
  • [26] Chemogenomics for drug discovery: clinical molecules from open access chemical probes
    Quinlan, Robert B. A.
    Brennan, Paul E.
    RSC CHEMICAL BIOLOGY, 2021, 2 (03): : 759 - 795
  • [27] DrugMatrix™ provides predictive chemogenomics solutions for safety assessment in drug discovery and development
    Gee, P
    DRUG METABOLISM REVIEWS, 2003, 35 : 166 - 166
  • [28] Drug-drug interaction discovery and demystification using Semantic Web technologies
    Noor, Adeeb
    Assiri, Abdullah
    Ayvaz, Serkan
    Clark, Connor
    Dumontier, Michel
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2017, 24 (03) : 556 - 564
  • [29] Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery
    Bajorath, Juergen
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (12) : 1371 - 1376
  • [30] Semantic Inference for Pharmacokinetic Drug-Drug Interactions
    Moitra, Abha
    Palla, Ravi
    Tari, Luis
    Krishnamoorthy, Mukkai
    2014 IEEE INTERNATIONAL CONFERENCE ON SEMANTIC COMPUTING (ICSC), 2014, : 92 - 95